Tardive dysphoria: The role of long term antidepressant use in-inducing chronic depression

Medical Hypotheses

Volumn 76, Issue 6, 2011, Pages 769-773

  El Mallakh, Rif S ^a   Gao, Yonglin ^a   Jeannie Roberts, R ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CHRONIC DISEASE; DEPRESSION; DRUG EFFICACY; DYSPHORIA; HUMAN; LONG TERM CARE; MEDLINE; TACHYPHYLAXIS; TARDIVE DYSKINESIA; TARDIVE DYSPHORIA;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSION; HUMANS; MOVEMENT DISORDERS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 79955719186     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.020     Document Type: Article

References (84)

1. Murray C., Lopez A.D. The global burden of disease 1996, Harvard University Press, Cambridge, Mass.
2. Keller M.B. Issues in treatment-resistant depression. J Clin Psychiatry 2005, 66(Suppl. 8):5-12.
3. Kocsis J.H. Recurrent depression: patient characteristics, clinical course, and current recommendations for management. CNS Spectrums 2006, 11(12 Suppl. 15):6-11.
4. Angst J. The course of affective disorders. Psychopathology 1986, 19(Suppl. 2):47-52.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000. p. 339-42.
6. Posternak M.A., Solomon D.A., Leon A.C., et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Mental Dis 2006, 194:324-329.
7. Coryell W., Endicott J., Keller M. Outcome of patients with chronic affective disorder: a five-year follow up. Am J Psych 1990, 147:1627-1633.
8. Hirschfield R.M.A. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994, 55(Suppl. 12):61-69.
9. Thase M., Sullivan L. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995, 4(4):261-277.
10. Solomon D.A., Keller M.B., Leon A.C., et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000, 157:229-233.
11. Bockting C.L., Spinhoven P., Koeter M.W.J., Wouters L.F., Schene A.H. Depression Evaluation Longitudinal Therapy Assessment Study Group: prediction of recurrence on recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J Clin Psychiatry 2006, 67:747-755.
12. Reynolds C.F., Frank E., Perel J.M., et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59years. JAMA 1999, 281:39-45.
13. Keller M.B., Kocsis J.H., Thase M.E., et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998, 280:1665-1672.
14. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(Suppl. 4):1-45.
15. Prien R.F., Kupfer D.J., Mansky P.A., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984, 41:1096-1104.
16. Thase M.E., Rush A.J. Treatment-resistant depression. Psychopharmacology: the fourth generation of progress 1995, 1081-1097. Raven Press, Ltd., New York, NY. R.E. Bloom, D.J. Kupfer (Eds.).
17. Shelton R.C., Tollefson G.D., Tohen M., et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158:131-134.
18. Keitner G.I., Ryan C.E., Solomon D.A. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006, 67:1412-1421.
19. Burrows G.D., Norman T.R., Judd F.K. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994, 9(Suppl. 2):5-10.
20. Surja A.A.S., El-Mallakh R.S. Fertility and childhood bipolar disorder. Med Hypotheses 2007, 69(3):587-589.
21. Hirschfeld R.M., Keller M.B., Panico S., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997, 277:333-340.
22. Byrne S.E., Rothschild A.J. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1998, 59:279-288.
23. Fava G.A. Can long-term treatments with antidepressant drugs worsen the course of depression?. J Clin Psychiatry 2003, 64:123-133.
24. Sharma V. Treatment resistance in unipolar depression: is it an iatrogenic phenomenon caused by antidepressant treatment of patients with a bipolar diathesis?. Med Hypotheses 2006, 67:1142-1145.
25. Lieb J., Balter A. Antidepressant tachyphylaxis. Med Hypotheses 1984, 15:279-291.
26. Cohen B., Baldessarini R. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 1985, 142:489-490.
27. Nierenberg A.A., Alpert J.E. Depressive breakthrough. Psychiatr Clin North Am 2000, 23(4):731-742.
28. Solomon D., Leon A.C., Mueller T.I., et al. Tachyphalaxis in unipolar major depressive disorder. J Clin Psychiatry 2005, 66:283-290.
29. Posternak M.A., Zimmerman M. Dual reuptake inhibitors incur lower rates of Tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J Clin Psychiatry 2005, 66:705-707.
30. Reimherr F.W., Amsterdam J.D., Quitkin F.M., et al. Optimal length of continuation therapy in depression. Am J Psychiatry 1998, 155:1247-1253.
31. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord 2001, 64:99-106.
32. Lieb J. Antidepressant tachyphlaxis. J Clin Psychiatry 1990, 51:36.
33. Mann J.J. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 1983, 3:363-366.
34. Donaldson S. Tolerance to phenelzine and subsequent refractory depression: three cases. J Clin Psychiatry 1989, 50:33-35.
35. Fava G.A. Do antidepressant and antianxiety drugs increase chronicity in affective disorders?. Psychother Psychosom 1994, 61(3-4):125-131.
36. El-Mallakh R.S., Waltrip C., Peters C. Can long-term antidepressant use be depressogenic?. J Clin Psychiatry 1999, 60:263.
37. Van Scheyen J.D. Recurrent vital depressions. Psychiatr Neurol Neurochir 1973, 76:93-112.
38. Di Mascio A., Meyer R.E., Stifler L. Effect of imipramine in individuals varying in levels of depression. Am J Psychiatry 1968, 127(Suppl.):55-58.
39. Aronson T.A. Treatment emergent depression with antidepressants in panic disorder. Compr Psychiatry 1989, 30:267-271.
40. Fux M., Taub M., Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993, 88:235-237.
41. Fava G.A., Bernardi M., Tomba E., Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007, 10:835-838.
42. Healy D. Emergence of antidepressant induced suicidality. Prim Care Psychiatry 2000, 6:23-28.
43. El-Mallakh R.S., Karippot A. Chronic depression in bipolar disorder. Am J Psychiatry 2006, 163:1137-1341.
44. El-Mallakh R.S., Karippot A. Antidepressant-associated chronic irritable dysphoria (ACID) in bipolar disorder: a case series. J Affect Disord 2005, 84:267-272.
45. Akiskal H.S., Mallya G. Criteria for the " soft" bipolar spectrum: treatment implications. Psychopharmacol Bull 1987, 23:68-73.
46. Ghaemi S.N., Ostacher M.M., El-Mallakh R.S., et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010, 71(4):372-380.
47. Khot V., Wyatt R.J. Not all that moves is tardive dyskinesia. Am J Psychiatry 1991, 148:661-666.
48. Elliot K.J., Lewis S., El-Mallakh R.S., et al. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia. Ann Clin Psychiatry 1994, 6:197-203.
49. Kane J.M., Woerner M., Weinhold P., Wegner J., Kinon B. A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982, 2:345-349.
50. Woerner M.G., Alvir J.M.J., Saltz B.L., Lieberman J.A., Kane J.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998, 155:1521-1528.
51. Tenback D.E., van Harten P.N., Slooff C.J., van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006, 163:1438-1440.
52. Soares-Weiser K., Fernandez H.H. Tardive dyskinesia. Semin Neurol 2007, 27:159-169.
53. Jeste D.V., Dolder C.R. Medication-induced movement disorders. Psychiatry 2003, 1666-1668. Wiley, West Sussex, England. 2nd ed. A. Tasman, J. Kay, J.A. Lieberman (Eds.).
54. Bunney B.S., Grace A.A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978, 23:1715-1727.
55. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983, 3:1607-1619.
56. Kane J.M. Tardive dyskinesia circa 2006. Am J Psychiatry 2006, 163(8):1316-1318.
57. Meshul C.K., Casey D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 1989, 489:338-346.
58. Pigott H.E., Leventhal A.M., Alter G.S., Boren J.J. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010, 79(5):267-279.
59. Fava M., Rappe S.M., Pava J.A., Nierenberg A.A., Alpert J.E., Rosenbaum J.F. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995, 56:52-55.
60. Schmidt M.E., Fava M., Zhang S., Gonzales J., Raute N.J., Judge R. Treatment approaches to major depressive disorder relapse, part I: dose increase. Psychother Psychosom 2002, 71:190-194.
61. Poirier M.F., Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomized comparison. Br J Psychiatry 1999, 175:12-16.
62. Thase M.E., Blomgren S.L., Birkett M.A., Apter J.T., Tepner R.G. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997, 58:16-21.
63. Maes M., Vandoolaeghe E., Densnyder R. Efficacy of treatment with trazadone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996, 41:201-210.
64. Blier P., Ward H.E., Tremblay P., Laberge L., Hébert C., Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167:281-288.
65. Bschor T., Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010, 121(3):174-179.
66. Siegel S., Baptista M.A., Kim J.A., McDonald R.V., Weise-Kelly L. Pavlovian psychopharmacology: the associative basis of tolerance. Exp Clin Psychopharmacol 2000, 8(3):276-293.
67. Heils A., Teufel A., Petri S., et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm 1995, 102:247-254.
68. Heils A., Teufel A., Petri S., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66:2621-2624.
69. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
70. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
71. Wilhelm K., Mitchell P.B., Niven H., et al. Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 2006, 188:210-215.
72. Jacobs N., Kenis G., Peeters F., Deron C., Vlietinck R., van Os J. Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006, 63:989-996.
73. Murphy G.M., Hollander S.B., Rodrigues H.E., Kremer C., Schatzberg A.F. Effects of the serotonin transporter gene promoter polymorphism on mirtrazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004, 61:1163-1169.
74. Durham L.K., Webb S.M., Milos P.M., Clary C.M., Seymour A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berlin) 2004, 174(4):525-529.
75. Yu Y.W., Tsai S.J., Chen T.J., Lin C.H., Hong C.J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002, 7:1115-1119.
76. Pollock B.G., Ferrell R.E., Mulsant B.H., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
77. El-Mallakh R.S., Peters C., Waltrip C. Antidepressant treatment and neural plasticity. J Child Adoles Psychopharmacol 2000, 10:287-294.
78. Baker M.W., Croll R.P. Modulation of in vivo neuronal sprouting by serotonin in adult CNS of the snail. Cell Mol Neurobiol 1996, 16:561-576.
79. Lira A., Zhou M., Castanon N., et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 2003, 54(10):960-971.
80. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
81. Voineskos A.N., Wilson A.A., Boovariwala A., et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berlin) 2007, 193(4):539-545.
82. Meyer J.H., Wilson A.A., Sagrati S., et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161(5):826-835.
83. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003, 4(12):1002-1012.
84. Ruhé H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12(4):331-359.